Category Archives: Biotechnology

Bioverativ (NASDAQ:BIVV) announces that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400M plus assumed cash.

As part of the acquisition, Bioverativ will obtain worldwide rights to True Norths lead candidate, TNT009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD).

In May 2017, the FDA granted TNT009 breakthrough therapy designation for the treatment of hemolysis in patients with primary CAD, and plans for the full clinical development program.

The acquisition of True North advances the Company's vision of becoming the leading rare disease company focused on blood disorders.

TNT009 has also received orphan drug designation from the FDA and the European Medicines Agency.

Bioverativ will hold a conference call at 8:30 a.m. ET to discuss the transaction.

Follow this link:
Bioverativ to acquire clinical-stage rare disease biotechnology company, True North Therapeutics - Seeking Alpha

Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup NY Stock News Puma Biotechnology, Inc. (PBYI) has been having a set of eventful trading activity and it is clear from an examination of the charts that traders are now fully aware of the company's key metrics. A deeper exploration of the setup is sure to yield a ... and more »

Read the rest here:
Puma Biotechnology, Inc. (PBYI) Has Finally Shown Its Full Hand Via The Chart Setup - NY Stock News

BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl

** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility

** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds

** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents

** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week

** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data

** Five analysts rate PBYI shares a "buy" or "strong buy", two rate "hold", according to TR data; median price target is $80

** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index

(This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.)

RELATED

Shudder

AD BY AVANIR 2016 Avanir Pharmaceuticals, Inc, All Rights Reserved. Avanir is a trademark or Avanir Pharmaceuticals, Inc.

Eos

Read more:
Puma Biotechnology: Shares on the prowl - Times of India

As of late, the Street has taken a bit closer look at shares of Prana Biotechnology Limited (NASDAQ:PRAN). In the latest session the stock moved-6.63%, putting the stock value at$2.24.

Most investors are likely looking for that next stock that is ready to take off running. Maybe the focus is on finding a stock that has recently taken a turn for the worse for no real apparent reason. As we all know, as quickly as a stock can drop in price, it can bounce back just as fast.

Although the popular stocks that receive a high level of media coverage tend to recover quicker after a sell-off, there may be plenty of under the radar stocks that are ripe for buying. Scoping out these potential market gems may help repair a portfolio that has taken a hit for any number of reasons.

Is Prana Biotechnology Limited Ready to Move higher? Sign Up For Breaking Alerts on this Stock Before the Crowd.

The average investor might not have the time to monitor every single tick of a given stock, but taking a look at historical performance may help provide some valuable insight on where the stock may be trending in the future. Over the past week, Prana Biotechnology Limited (NASDAQ:PRAN) has performed 0.90%. For the past month, shares are -20.85%. Over the last quarter, shares have performed -3.03%. Looking back further, Prana Biotechnology Limited stock has been -23.29% over the last six months, and 37.42% since the start of the calendar year. For the past full year, shares are -38.63%.

There is rarely any substitute for diligent research, especially when it pertains to the equity markets. No matter what strategy an investor employs, keeping abreast of current market happenings is of the utmost importance. Everyone wants to see their stock picks soar, but the stark reality is that during a market wide sell-off, this may not be the case. Recently, shares of Prana Biotechnology Limited (NASDAQ:PRAN)have been seen trading -27.98% away from the 200-day moving average and -14.63% off the 50-day moving average. The stock is currently trading -66.52% away from the 52-week high and separated 47.37% from the 52-week low. Prana Biotechnology Limiteds RSI is presently sitting at 40.44.

New investors may sometimes be working with limited capital. Choosing which stocks to own can be a tough decision. Individuals may be deciding on whether to buy 10 shares of a stock trading at $100 as opposed to purchasing 100 shares of a stock trading at $10. We have recently been focusing on stocks that are trading under the $10 price level. We are constantly monitoring technical and fundamental factors that may lead to breakouts for these relatively cheap (in terms of price) stocks.

More here:
Looking For a Catalyst: Update on Prana Biotechnology Limited (NASDAQ:PRAN) - Morgan Research

On May 4, 2017, Puma announced the resignation of its Senior Vice President, Regulatory Affairs, effective as of May 15, 2017, less than two weeks before the FDA's scheduled review of neratinib. On May 5, 2017, Fox Business published an article reporting that a large number of patients taking neratinib suffered from severe side effects, posing a safety risk for the drug.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Puma shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: bsachsmichaels@hfesq.com Website: http://www.hfesq.com Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-puma-biotechnology-inc-300460923.html

SOURCE Harwood Feffer LLP

http://www.hfesq.com

See the original post here:
Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc. - PR Newswire (press release)

Investopedia

Harbour Investment Management LLC Invests $4.559 Million in iShares NASDAQ Biotechnology Index (IBB) The Cerbat Gem iShares NASDAQ Biotechnology Index logo Harbour Investment Management LLC bought a new position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent filing with the Securities and Exchange ... Lucas Capital Management Has $2.254 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Sports Perspectives The Caldwell & Orkin Inc. Acquires Shares of 2,600 iShares ...BangaloreWeekly Davidson & Garrard Inc. Lowers Stake in iShares NASDAQ Biotechnology Index (IBB)Markets Daily BBNS -Transcript Daily -Chaffey Breeze all 30 news articles »

See original here:
Harbour Investment Management LLC Invests $4.559 Million in iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

China will evaluate eight pending U.S. agricultural biotechnology product applications by the end of May, potentially opening the door for sales by Dow AgroSciences, DuPont Pioneer, Monsanto, and Syngenta.

China agreed to conduct the evaluations as part of an agreement unveiled by the White House on May 12. The two countries reached the trade deal after a meeting in April between U.S. President Donald J. Trump and Chinese President Xi Jinping.

U.S. officials have prodded China for years to speed up its lengthy process for deciding whether to approve the import of new genetically modified (GM) crops. It typically takes six years to win Chinese clearance of a GM variety, twice as long as other major nations take.

Under the new deal, Chinas National Biosafety Committee will meet by the end of May to assess the safety of eight products made by four major U.S. agrochemical companies.

Dow AgroSciences is seeking approval for its corn and soybean seeds, while Syngenta and DuPont Pioneer have each applied to sell a GM corn variety in China. Monsanto makes four of the products pending approval, including herbicide-tolerant corn, soybeans, and two alfalfa varieties that have been under review for nearly six years.

The Biotechnology Innovation Organization (BIO), an industry trade group, wants to make sure China lives up to its commitment.

The ultimate test of success will be for China to follow its process and quickly approve the eight pending biotechnology applications and establish a synchronized, timely, and predictable process going forward, says Joseph Damond, senior vice president for international affairs at BIO.

View post:
China agrees to review US biotechnology applications - Chemical & Engineering News

FinancialsTrend

Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) StockNewsJournal Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $36.25, up from yesterday's close by 13.46%. Given the stock's recent action ... Reasons to Add Puma Biotechnology (PBYI) to Portfolio NowNasdaq Does Puma Biotechnology Inc. (NASDAQ:PBYI) deserve your investment?FinancialsTrend Puma Biotechnology Inc (PBYI) Soars 6.21% on May 18Equities.com TopChronicle -BBNS -PharmiWeb.com (press release) all 28 news articles »

See the article here:
Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) - StockNewsJournal

USA Commerce Daily

Puma Biotechnology, Inc. (PBYI): Some of the key technical areas USA Commerce Daily With all other things going on, Puma Biotechnology, Inc. (NASDAQ:PBYI) has been on a free fall declining -4.23 percent in just three months. It looks like traders are not happy with the stock. On the other side, analysts now consider Puma ... and more »

See original here:
Puma Biotechnology, Inc. (PBYI): Some of the key technical areas - USA Commerce Daily

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham.

With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP).

"Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency."

Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank.

"We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region."

A groundbreaking ceremony for the expansion was held in April, but actual construction has yet to begin. Before work could begin in earnest, Bush said Thursday afternoon the plans need to go before the Buckingham Board of Supervisors for final land development approval.

The Biotechnology Center is credited with contributing approximately $1.8 billion to the local economy and supporting more than 700 jobs since its creation in 2007. A partnership with the Hepatitis B Foundation and Delaware Valley University started the initiative, but disagreements on the center's management ended the relationship.

The Hepatitis B Foundation bought out the university's interests in the center for $2 million in October, ending the disagreement and restarting the stalled expansion plans.

Link:
Bucks commissioners OK state award of $2 million for Pa. Biotechnology Center expansion - The Intelligencer